bullish

Samsung Biologics - Decent Earnings, Successful Contract Wins in Q1

332 Views26 Apr 2024 19:01
Broker
1Q24 reports consolidated revenue of W946.9bn(+31% yoy), OP of W221.3bn (+15% yoy). Beat consensus owing to an increase in plant 4 operation rate and new bs product sales
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Daishin Securities
External broker reports(aggregated public sources)
Daishin Securities
South KoreaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Samsung Biologics - Decent Earnings, Successful Contract Wins in Q1
    26 Apr 2024
x